MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Management of In-Stent Restenosis After DES Use
Insights on current mechanisms and strategies for treatment.
By Vineet Bhatia, MD, DM, DNB, MNAMS, and Upendra Kaul, MD, DM, FCSI, FSCAI, FACC, FAMS
SMT’s Tetrilimus Ultrathin EES Evaluated at 3 and 6 Months in EverOCT Study
June 14, 2021—Sahajanand Medical Technologies Limited (SMT) announced publication of 3- and 6-month results from the EverOCT study of the company’s Tetrilimus everolimus-eluting stent (EES) by optical coherence tomography (OCT) analysis.
SMT’s TUXEDO-2 Trial of Supraflex Cruz DES Completes Enrollment in India
August 16, 2024—Sahajanand Medical Technologies (SMT) announced the completion of patient enrollment for the TUXEDO-2 clinical trial.
Chief Medical Editor's Page: DES Evolution
By Ted E. Feldman, MD, FSCAI
TUXEDO Trial Compares EES and PES in Diabetic Patients With CAD
October 14, 2015—Results of the TUXEDO trial, which compared two types of drug-eluting stents in diabetic patients, were reported at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation being held October 11–15, in San Francisco, California.
TUXEDO-2 Evaluates PCI With Ultrathin Stents in Diabetic Patients With Multivessel Disease
November 10, 2025—Percutaneous coronary intervention (PCI) using contemporary drug-eluting stents (DESs) demonstrated favorable safety and efficacy outcomes in diabetic patients with multivessel disease (MVD), according to results of the TUXEDO-2 trial.
